Joel Randolph Hecht, MD

J. Randolph Hecht
Gastroenterology, Medical Oncology
Male
English
Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica
G63119
(888) 662-8252, Hem/Onc info. and appointments
(310) 829-5471 Gastrointestinal Oncology information
2020 Santa Monica Blvd., Suite 600
Santa Monica, CA 90404
Medical Oncology, UCLA School of Medicine, 1995 - 1997
Medicine/Gastroenterology, UCLA School of Medicine, 1988 - 1991
Internal Medicine, Northwestern University Feinberg School of Medicine, 1985 - 1987
Internal Medicine, Northwestern University Feinberg School of Medicine, 1984 - 1985
MD, Eastern Virginia Medical School, 1984
| Cancers of the Digestive Tract |
Director, Gastrointestinal Oncology Program
Physician, Hematology / Oncology, Colorectal Cancer Treatment Program, UCLA Center for Esophageal Disorders, UCLA Santa Monica Hematology Oncology at 2020
ACADEMIC /PROFESSIONAL TITLES
- Professor of Clinical Medicine,David Geffen School of Medicine at UCLA
- Director of the UCLA Gastrointestinal Oncology Program
BIO
Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents.
Our staff will assist you in selecting the appropriate UCLA clinical department for your patient.
Find out how to refer a patient
















